One thing that stands out about Recursion right away is how the company refers to itself. Recursion doesn't say that it's a pharmaceutical, biopharmaceutical, or biotech company. Instead, it uses the ...

Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...

Pinker's new book reveals how recursive mentalizing—thinking about thinking—may be the hidden engine of human life, from ...

In the latest close session, Recursion Pharmaceuticals (RXRX) was down 5.42% at $5.23. The stock fell short of the S&P 500, which registered a loss of 0.38% for the day. Meanwhile, the Dow experienced ...

Recursion Pharmaceuticals (RXRX) shares ended the last trading session 8.2% higher at $5.52. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Greenlight Capital funds returned -3.6% in Q3 2025, net of fees and expenses, compared to 8.1% for the S&P 500 index, ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the Best Penny Stocks to Buy with the Highest Upside Potential. On September 10, Gil Blum from Needham reiterated a Buy rating on Recursion ...